Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 24, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

NCT01094262
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
Oxycodone CR (standard pain medication), JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

NCT01841996
View directory record Official record
Conditions
Onychomycosis
Interventions
ME1111 solution, Vehicle Solution
Drug
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 24, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional Results available

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

NCT01467076
View directory record Official record
Conditions
Prematurity, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
Interventions
Aerosolized Normal Saline, Inhaled PGE1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 24, 2026, 4:47 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

NCT03098420
View directory record Official record
Conditions
Post Surgical Pain
Interventions
2mg Dexamethasone, 4mg Dexamethasone, Ropivacaine (TAP blocks), Morphine, Bupivacaine Hydrochloride, Normal saline 1ml, Normal saline 0.5ml
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 24, 2026, 4:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

NCT05740280
View directory record Official record
Conditions
Healthy Volunteers
Interventions
iCP-NI, Placebo
Drug
Lead sponsor
Cellivery Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Not applicable Interventional

PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS

NCT05296096
View directory record Official record
Conditions
Muscle Loss, Protein, Mobility, Pediatric ALL
Interventions
Protein dosage and rehabilitation team delivered exercise prescription
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 4:47 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis

NCT05092646
View directory record Official record
Conditions
Ankle Osteoarthritis
Interventions
Axolotl Ambient, "Drug/Placebo: 0.9% Normal Saline"
Biological · Drug
Lead sponsor
Axolotl Biologix
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Boise, Idaho • Shreveport, Louisiana • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

NCT02756624
View directory record Official record
Conditions
Healthy Subjects
Interventions
AC-170 0.24%, AC-170 Vehicle
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

NCT04934124
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ITI-333, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

NCT00694382
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Semuloparin sodium, Placebo (for semuloparin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
48
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Computer-Mediated Versus Face-to-Face Motivational-Type Interviews

NCT06945471
View directory record Official record
Conditions
Marijuana Use
Interventions
1) Face-to-face, and 2) Computer-mediated motivational type interviews
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years to 29 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 24, 2026, 4:47 PM EDT
Recruiting Phase 4 Interventional

Randomized Controlled Trial for Ankle Fracture Pain Control

NCT03696199
View directory record Official record
Conditions
Ankle Fractures
Interventions
Long-Acting Local Anesthesia, Regional Anesthesia
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780463
View directory record Official record
Conditions
COVID-19
Interventions
MP0420, Placebo, Remdesivir
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
73
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Not applicable Interventional Results available

A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50

NCT04192630
View directory record Official record
Conditions
Cataract
Interventions
CVisc50 OVD, ProVisc OVD, Cataract Surgery
Device · Procedure
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
45 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
22
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02807428
View directory record Official record
Conditions
Post-surgical Pain
Interventions
AYX1 Injection 660 mg/6 mL, Placebo Injection 6 mL
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 24, 2026, 4:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

NCT06325332
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Nirsevimab
Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
0 Days to 12 Months
Enrollment
49,680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

NCT06481098
View directory record Official record
Conditions
Obesity
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05130047
View directory record Official record
Conditions
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea, Bile Acid Malabsorption Syndrome Type II, Functional Diarrhea
Interventions
Aldafermin, Placebo
Drug
Lead sponsor
Michael Camilleri, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 24, 2026, 4:47 PM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT03404115
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Waterbury, Connecticut • Indianapolis, Indiana • Lewiston, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 24, 2026, 4:47 PM EDT
Active, not recruiting Phase 2 Interventional

Peripheral Modulation of Muscle Stiffness and Spasticity

NCT03306615
View directory record Official record
Conditions
Muscle Spasticity
Interventions
Hyaluronidase, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 4:47 PM EDT